摘要
随着分子检测技术的广泛应用,急性髓系白血病(AML)中许多有独立预后意义的分子标志被检测出来,基于分子标志的新亚型如核心结合因子相关的AML(CBF-AML)、FMS样的酪氨酸激酶3相关的AML(FLT3-AML)被确立。AML中许多与表观遗传学异常相关的重现性基因突变也得以发现。这些发现有助于深入研究AML发病机制并提供新的治疗靶点。本文除介绍2014年NCCN的AML和急性早幼粒细胞白血病治疗指南外,也分别介绍CBF-AML、FLT3-AML以及针对AML中表观遗传学异常的治疗进展。
Research in molecular genetics has been instrumental in deciphering the molecular heterogeneity of acute myeloid leukemia（AML）,in particular,the new subtypes of core-binding factor AML（CBF-AML）and FLT3 AML have been identified.Many recurrent mutations in genes encoding proteins involved in the epigenetic regulation of transcription in most patients with AML have also been founded.This discovery has led to new insights into the role of the epigenome in AML and opens the possibility of epigenetically targeted therapies.This paper describes 2014 NCCN guidelines of AML and acute promyelocytic leukemia and treatment strategies for CBF-AML and FLT3-AML and epigenetically targeted therapies.
出处
《临床荟萃》
CAS
2015年第2期157-160,共4页
Clinical Focus
关键词
白血病
髓样
基因
抗肿瘤联合化疗方案
分子靶向治疗
预后
leukemia
myeloid
gene
antineoplastic combined chemotheray protocols
molecular targeted therapy
prognosis
